Kidney Transplant Rejection Market Summary
The Kidney Transplant Rejection market is witnessing a significant upswing, reflecting the growing burden of End-Stage Renal Disease (ESRD) and the expanding pool of kidney transplant recipients worldwide. The Kidney Transplant Rejection Market Size in the 7 Major Markets (7MM) is expected to grow from USD 4,260 million in 2025 to USD 6,647 million in 2034, registering a CAGR of 5.07% during the forecast period across leading countries including the US, EU4 nations (Germany, France, Italy, and Spain), the UK, and Japan.
Kidney Transplant Rejection Overview
Kidney transplant rejection occurs when the recipient’s immune system identifies the transplanted organ as foreign and mounts an immune attack, threatening graft function and long-term survival. While kidney transplantation remains the gold standard for treating ESRD and advanced Chronic Kidney Disease (CKD) – offering superior survival rates and quality of life compared to dialysis – its success hinges on precise donor-recipient matching and robust immunosuppressive management.
Rejection is primarily driven by T lymphocytes through innate and adaptive immune mechanisms, amplified by costimulatory molecules and cytokines. The underlying causes include nonadherence to immunosuppressive therapy, infections triggering immune activation, HLA incompatibility, blood type mismatches, and immune responses such as acute cellular or chronic antibody-mediated rejection (AMR). Donor-specific antibodies, younger recipient age, delayed graft function, and non-compliance with prescribed medications are among the critical risk factors that compound the risk.
Key symptoms include decreased urine output, swelling in the legs or feet, hypertension, fatigue, fever, chills, nausea, and tenderness over the transplant site. Elevated creatinine levels further indicate impaired kidney function. If untreated, these signs can precipitate reduced graft function, graft failure, and eventual reliance on dialysis.
Download the comprehensive Kidney Transplant Rejection market report and unlock actionable insights for your strategic decisions now.
Kidney Transplant Rejection Diagnosis
Kidney transplant rejection is diagnosed through kidney biopsy and classified using the Banff system, which identifies subtypes including Antibody-mediated rejection (AMR) and T cell-mediated rejection (TCMR). Complementary diagnostic tools include blood tests for creatinine and blood urea nitrogen (BUN), urine tests for biomarkers such as NGAL, and non-invasive imaging modalities such as ultrasound, MRI, and PET scans. In AMR cases, histological and serological evidence are both used for confirmation, while acute TCMR is identified through biopsy demonstrating cellular infiltration patterns.
Kidney Transplant Rejection Treatment
Treatment of kidney transplant rejection adopts a multi-faceted approach tailored to the rejection type and severity:
- Hyperacute rejection, being irreversible, necessitates immediate removal of the transplanted organ
- Acute TCMR responds to corticosteroids and T-cell-depleting agents such as rabbit anti-thymocyte globulin
- AMR is managed with plasmapheresis, intravenous immunoglobulin (IVIG), and monoclonal antibodies targeting B cells or plasma cells
- Standard immunosuppressive regimens incorporate calcineurin inhibitors such as tacrolimus, antimetabolites including mycophenolic acid, and corticosteroids
- Chronic rejection remains a persistent challenge, underscoring the need for emerging therapies and ongoing research
Kidney Transplant Rejection Epidemiology
Drawing from a patient-based model, Kidney Transplant Rejection market research reveals the following key epidemiological findings across the 7MM for the period 2020–2034:
- In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, a number expected to rise by 2034
- Approximately 27 thousand incident cases of kidney transplants were recorded across the US in 2023
- The US reported approximately 2 thousand acute and 8 thousand chronic kidney transplant rejection cases in 2023, with both figures projected to increase by 2034
- Among EU4 countries and the UK, the UK reported the highest number of living kidney transplants in 2023 at approximately 46 thousand, followed by France at nearly 45 thousand; Italy recorded the lowest at around 28 thousand
- EU4 and the UK reported approximately 2 thousand acute and 4 thousand chronic rejection cases in 2023; by 2034, these figures are projected to rise to nearly 4 thousand acute and 7 thousand chronic cases
- Japan reported approximately 2 thousand incident kidney transplant cases in 2023, projected to grow at a CAGR of 0.7% through 2034
Recent Developments in Kidney Transplant Rejection Clinical Trials
- In February 2025, the US FDA approved clinical trials to transplant organs from genetically modified pigs into patients with kidney failure; United Therapeutics Corp. will enroll six initial patients with end-stage renal disease, expanding to 50 participants, with a 24-week post-transplant safety assessment and lifelong tracking of outcomes
- Positive interim Phase III data for MDR-101 (Medeor Therapeutics) was presented at ASN Kidney Week in November 2023, highlighting its potential as a cellular therapy to induce donor-specific immune tolerance
- Eledon Pharmaceuticals completed enrollment for the Phase II BESTOW trial for Tegoprubart four months ahead of schedule in September 2024, with topline results anticipated in Q4 2025
- Phase Ib trial data for Tegoprubart presented at the American Transplant Congress in June 2024 demonstrated the drug’s safety and tolerability profile
Leading Kidney Transplant Rejection Companies
Key companies developing therapies in this space include Medeor Therapeutics, Eledon Pharmaceuticals, Sanofi, TRACT Therapeutics, Sangamo Therapeutics, Asahi Kasei (Veloxis Pharmaceuticals), Bristol Myers Squibb, and Azurity Pharmaceuticals, among others.
Kidney Transplant Rejection Marketed Drugs
MYHIBBIN (Azurity Pharmaceuticals) – The first ready-to-use mycophenolate mofetil (MMF) oral suspension approved by the US FDA in May 2024 for preventing organ rejection in patients aged 3 months and older who received allogeneic kidney, heart, or liver transplants. It inhibits IMPDH, suppressing T and B lymphocyte proliferation and cytokine production.
THYMOGLOBULIN (Sanofi) – An immunosuppressive therapy derived from rabbit serum, targeting T lymphocyte antigens including CD2, CD3, CD4, and HLA-DR. Approved initially in Japan (2011), the EU (2013), and the US (2017), THYMOGLOBULIN holds Orphan Drug Designation (ODD) from the US FDA and remains a cornerstone therapy for reducing acute rejection rates and enhancing long-term graft survival.
NULOJIX (Bristol Myers Squibb) – A selective T-cell costimulation blocker (belatacept) approved by the US FDA and EMA in June 2011. It targets CD80 and CD86 on antigen-presenting cells, blocking CD28-mediated T-cell activation, reducing proliferation, and suppressing cytokine production including IL-2 and TNF-α.
Emerging Kidney Transplant Rejection Drugs
Reflecting critical Kidney Transplant Rejection market insight, the development pipeline features several high-potential candidates:
MDR-101 (Medeor Therapeutics) – A cellular therapy derived from the donor’s blood and peripheral stem cells, designed to induce donor-specific immune tolerance and eliminate the need for lifelong immunosuppression. MDR-101 holds ODD in both the US and EU, has received RMAT designation from the US FDA (September 2020), and was awarded USD 18.8 million by the California Institute for Regenerative Medicine (CIRM) for its Phase III trial. Estimates suggest MDR-101 is expected to generate approximately USD 332.8 million by 2034 in the 7MM.
Tegoprubart / AT-1501 (Eledon Pharmaceuticals) – A humanized monoclonal antibody targeting the CD40L pathway designed to replace traditional calcineurin inhibitors such as tacrolimus. Eledon secured a securities purchase agreement in May 2023 yielding up to USD 185 million in funding, including USD 35 million upfront and up to USD 105 million in milestone-based funding.
Riliprubart / SAR445088 (Sanofi) – An IgG4 humanized monoclonal antibody under Phase II evaluation for AMR in kidney transplants. It selectively inhibits activated complement component C1s, a critical mediator of inflammatory processes associated with AMR, administered intravenously.
Kidney Transplant Rejection Market Outlook
Reflecting evolving Kidney Transplant Rejection market trends, the treatment landscape has matured considerably, with an increased emphasis on personalized immunosuppressive strategies. Around 15–20% of transplant recipients experience some form of rejection, underscoring the critical importance of regular monitoring and strict adherence to therapy.
Key approved medications including ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT continue to anchor the treatment paradigm, while the pipeline – featuring MDR-101, Tegoprubart, Riliprubart, TRK-001 (Treg), TX200, and VEL-101 – is poised to transform long-term outcomes.
From a market size perspective:
- The total Kidney Transplant Rejection Market Size in the 7MM was approximately USD 3,970 million in 2023
- The US market alone was valued at approximately USD 2,448 million in 2023
- EU4 and the UK collectively accounted for approximately USD 1,423 million in 2023, representing nearly 36% of total 7MM revenue
- France led the EU4 and UK segment in 2023 with approximately USD 361 million, closely followed by the UK at around USD 360 million
- Japan’s market was valued at approximately USD 99 million in 2023, with growth projected through 2034
Kidney Transplant Rejection Drugs Uptake
The drugs uptake section of comprehensive market reports focuses on the anticipated uptake rates of potential therapies expected to enter the Kidney Transplant Rejection medicine market during 2020–2034, providing investors and stakeholders with a forward-looking perspective on revenue trajectory and competitive dynamics.
Discover how emerging therapies are transforming outcomes in the Kidney Transplant Rejection treatment landscape today.
Conclusion
The Kidney Transplant Rejection market stands at a pivotal inflection point, driven by a rising global transplant burden, advancements in immunological science, and an increasingly robust pipeline of targeted therapies. With chronic rejection remaining a formidable challenge and approximately 15–20% of recipients at risk, the urgency for innovative, durable treatment options has never been greater. The convergence of cellular therapies, monoclonal antibodies, and precision immunosuppression strategies promises to redefine long-term graft survival and patient quality of life in the coming decade.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
